Results 241 to 250 of about 185,500 (340)
Synaptophysin: A sensitive and specific marker for ganlion cells in central nervous system neoplasms
Douglas C. Miller +3 more
openalex +1 more source
Circular RNA PTPN4 Contributes to Blood‐Brain Barrier Disruption during Early Epileptogenesis
Epileptic condition induces CircPTPN4 upregulation, which promotes ECE‐1 expression through competitive sequestration of miR‐145a‐5p. The elevated ECE‐1 catalyzes the ET‐1 production, leading to p38/MAPK pathway activation and subsequent downregulation of tight junction protein expression. This cascade results in increased BBB permeability and enhanced
Jiurong Yang +16 more
wiley +1 more source
Multinodular and vacuolating neuronal tumors in epilepsy: dysplasia or neoplasia? [PDF]
An S +17 more
core
Nanoscale Mapping of the Subcellular Glycosylation Landscape
Using multiplexed super‐resolution imaging with fluorophore‐labeled lectins, this study reports intracellular glycosylation at the nanoscale across organelles and synaptic specializations. Extending glycan analysis beyond the cell surface, Glyco‐STORM reveals distinct glycosylation nanodomains in the ER, Golgi, lysosomes, and synaptic sites.
Helene Gregoria Schroeter +4 more
wiley +1 more source
Behavioral Changes as the Initial Presentation of Primary Central Nervous System Lymphoma: A Case Report. [PDF]
Manqaryos B, Shakhloul M, Amer A.
europepmc +1 more source
This study reveals that Urolithin A (UA) counteracts alcohol‐induced cognitive and social dysfunction (AICSD) via a gut microbiome‐dependent mechanism. UA‐enriched Bacteroids sartorii and Parabacteroids distasonis elevate anandamide (AEA), which activates the CB1R‐DRD2‐Rap1 signaling cascade to drive synaptic repair and reduce neuroinflammation ...
Hongbo Zhang +9 more
wiley +1 more source
Pediatric high-grade neuroepithelial BCOR tandem duplicated tumor: An illustrative case. [PDF]
Bui NE, Lubisich J, Tran DK.
europepmc +1 more source
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin +14 more
wiley +1 more source

